Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=234"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=234

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02389946-sae",
        "title": "Orsiro Sirolimus Coronary Stent System vs Xience Everolimus Coronary Stent System: serious adverse events",
        "summary": "548 of 884 against 293 of 450; risk difference -3.1 points, 95% interval -8.5 to 2.4; NCT02389946, Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions",
        "record": "/library/comparisons/NCT02389946-sae",
        "nct_id": "NCT02389946",
        "kind": "serious-adverse-events",
        "participants": 1334,
        "risk_difference": {
          "value": -0.031201608848667628,
          "lower": -0.08474598261239495,
          "upper": 0.023799932212360327
        },
        "group_1": "548 of 884",
        "group_2": "293 of 450",
        "difference": "-3.1 points",
        "interval": "-8.5 to 2.4",
        "trial_title": "Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions"
      },
      {
        "id": "NCT01266265-sae",
        "title": "Tyvaso vs Control: serious adverse events",
        "summary": "96 of 666 against 94 of 667; risk difference 0.3 points, 95% interval -3.4 to 4.1; NCT01266265, Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies",
        "record": "/library/comparisons/NCT01266265-sae",
        "nct_id": "NCT01266265",
        "kind": "serious-adverse-events",
        "participants": 1333,
        "risk_difference": {
          "value": 0.0032146089117603416,
          "lower": -0.03443215269918266,
          "upper": 0.040868712702665774
        },
        "group_1": "96 of 666",
        "group_2": "94 of 667",
        "difference": "0.3 points",
        "interval": "-3.4 to 4.1",
        "trial_title": "Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=235",
  "request_id": "O2AClv_uwpqI3rg_"
}